Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

GSK2801, a BAZ2/BRD9 Bromodomain Inhibitor, Synergizes with BET Inhibitors to Induce Apoptosis in Triple-Negative Breast Cancer.

Bevill SM, Olivares-Quintero JF, Sciaky N, Golitz BT, Singh D, Beltran AS, Rashid NU, Stuhlmiller TJ, Hale A, Moorman NJ, Santos CM, Angus SP, Zawistowski JS, Johnson GL.

Mol Cancer Res. 2019 Jul;17(7):1503-1518. doi: 10.1158/1541-7786.MCR-18-1121. Epub 2019 Apr 18.

PMID:
31000582
2.

Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.

Synodos for NF2 Consortium, Allaway R, Angus SP, Beauchamp RL, Blakeley JO, Bott M, Burns SS, Carlstedt A, Chang LS, Chen X, Clapp DW, Desouza PA, Erdin S, Fernandez-Valle C, Guinney J, Gusella JF, Haggarty SJ, Johnson GL, La Rosa S, Morrison H, Petrilli AM, Plotkin SR, Pratap A, Ramesh V, Sciaky N, Stemmer-Rachamimov A, Stuhlmiller TJ, Talkowski ME, Welling DB, Yates CW, Zawistowski JS, Zhao WN.

PLoS One. 2018 Jun 13;13(6):e0197350. doi: 10.1371/journal.pone.0197350. eCollection 2018.

3.

Proteomic analysis defines kinase taxonomies specific for subtypes of breast cancer.

Collins KAL, Stuhlmiller TJ, Zawistowski JS, East MP, Pham TT, Hall CR, Goulet DR, Bevill SM, Angus SP, Velarde SH, Sciaky N, Oprea TI, Graves LM, Johnson GL, Gomez SM.

Oncotarget. 2018 Jan 29;9(21):15480-15497. doi: 10.18632/oncotarget.24337. eCollection 2018 Mar 20.

4.

Enhancer remodeling regulates epigenetic adaptation and resistance to MEK1/2 inhibition in triple-negative breast cancer.

Bevill SM, Zawistowski JS, Johnson GL.

Mol Cell Oncol. 2017 Mar 31;4(6):e1300622. doi: 10.1080/23723556.2017.1300622. eCollection 2017.

5.

Kinome and Transcriptome Profiling Reveal Broad and Distinct Activities of Erlotinib, Sunitinib, and Sorafenib in the Mouse Heart and Suggest Cardiotoxicity From Combined Signal Transducer and Activator of Transcription and Epidermal Growth Factor Receptor Inhibition.

Stuhlmiller TJ, Zawistowski JS, Chen X, Sciaky N, Angus SP, Hicks ST, Parry TL, Huang W, Beak JY, Willis MS, Johnson GL, Jensen BC.

J Am Heart Assoc. 2017 Oct 19;6(10). pii: e006635. doi: 10.1161/JAHA.117.006635.

6.

Epigenetic Mechanisms Regulating Adaptive Responses to Targeted Kinase Inhibitors in Cancer.

Angus SP, Zawistowski JS, Johnson GL.

Annu Rev Pharmacol Toxicol. 2018 Jan 6;58:209-229. doi: 10.1146/annurev-pharmtox-010617-052954. Epub 2017 Sep 15. Review.

PMID:
28934561
7.

Pharmacologic targeting of drug-induced enhancers.

Zawistowski JS, Bevill SM, Johnson GL.

Oncoscience. 2017 Jun 22;4(5-6):43-44. doi: 10.18632/oncoscience.354. eCollection 2017 May. No abstract available.

8.

Landscaping a chromatin response to MEK inhibition.

Zawistowski JS, Goulet DR, Johnson GL.

Cell Cycle. 2017 Apr 18;16(8):731-732. doi: 10.1080/15384101.2017.1302232. Epub 2017 Mar 13. No abstract available.

9.

MAP3K4 Controls the Chromatin Modifier HDAC6 during Trophoblast Stem Cell Epithelial-to-Mesenchymal Transition.

Mobley RJ, Raghu D, Duke LD, Abell-Hart K, Zawistowski JS, Lutz K, Gomez SM, Roy S, Homayouni R, Johnson GL, Abell AN.

Cell Rep. 2017 Mar 7;18(10):2387-2400. doi: 10.1016/j.celrep.2017.02.030.

10.

Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.

Zawistowski JS, Bevill SM, Goulet DR, Stuhlmiller TJ, Beltran AS, Olivares-Quintero JF, Singh D, Sciaky N, Parker JS, Rashid NU, Chen X, Duncan JS, Whittle MC, Angus SP, Velarde SH, Golitz BT, He X, Santos C, Darr DB, Gallagher K, Graves LM, Perou CM, Carey LA, Earp HS, Johnson GL.

Cancer Discov. 2017 Mar;7(3):302-321. doi: 10.1158/2159-8290.CD-16-0653. Epub 2017 Jan 20.

11.

Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains.

Stuhlmiller TJ, Miller SM, Zawistowski JS, Nakamura K, Beltran AS, Duncan JS, Angus SP, Collins KA, Granger DA, Reuther RA, Graves LM, Gomez SM, Kuan PF, Parker JS, Chen X, Sciaky N, Carey LA, Earp HS, Jin J, Johnson GL.

Cell Rep. 2015 Apr 21;11(3):390-404. doi: 10.1016/j.celrep.2015.03.037. Epub 2015 Apr 9.

12.

Assessing adaptation of the cancer kinome in response to targeted therapies.

Zawistowski JS, Graves LM, Johnson GL.

Biochem Soc Trans. 2014 Aug;42(4):765-9. doi: 10.1042/BST20130274. Review.

13.

Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.

Johnson GL, Stuhlmiller TJ, Angus SP, Zawistowski JS, Graves LM.

Clin Cancer Res. 2014 May 15;20(10):2516-22. doi: 10.1158/1078-0432.CCR-13-1081. Epub 2014 Mar 24.

14.

A RhoC biosensor reveals differences in the activation kinetics of RhoA and RhoC in migrating cells.

Zawistowski JS, Sabouri-Ghomi M, Danuser G, Hahn KM, Hodgson L.

PLoS One. 2013 Nov 5;8(11):e79877. doi: 10.1371/journal.pone.0079877. eCollection 2013.

15.

Automated line scan analysis to quantify biosensor activity at the cell edge.

Allen RJ, Tsygankov D, Zawistowski JS, Elston TC, Hahn KM.

Methods. 2014 Mar 15;66(2):162-7. doi: 10.1016/j.ymeth.2013.08.025. Epub 2013 Aug 30.

16.

SWI/SNF chromatin-remodeling factor Smarcd3/Baf60c controls epithelial-mesenchymal transition by inducing Wnt5a signaling.

Jordan NV, Prat A, Abell AN, Zawistowski JS, Sciaky N, Karginova OA, Zhou B, Golitz BT, Perou CM, Johnson GL.

Mol Cell Biol. 2013 Aug;33(15):3011-25. doi: 10.1128/MCB.01443-12. Epub 2013 May 28.

17.

MicroRNA 9-3p targets β1 integrin to sensitize claudin-low breast cancer cells to MEK inhibition.

Zawistowski JS, Nakamura K, Parker JS, Granger DA, Golitz BT, Johnson GL.

Mol Cell Biol. 2013 Jun;33(11):2260-74. doi: 10.1128/MCB.00269-13. Epub 2013 Mar 25.

18.

Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer.

Duncan JS, Whittle MC, Nakamura K, Abell AN, Midland AA, Zawistowski JS, Johnson NL, Granger DA, Jordan NV, Darr DB, Usary J, Kuan PF, Smalley DM, Major B, He X, Hoadley KA, Zhou B, Sharpless NE, Perou CM, Kim WY, Gomez SM, Chen X, Jin J, Frye SV, Earp HS, Graves LM, Johnson GL.

Cell. 2012 Apr 13;149(2):307-21. doi: 10.1016/j.cell.2012.02.053.

19.

Defining the expressed breast cancer kinome.

Midland AA, Whittle MC, Duncan JS, Abell AN, Nakamura K, Zawistowski JS, Carey LA, Earp HS 3rd, Graves LM, Gomez SM, Johnson GL.

Cell Res. 2012 Apr;22(4):620-3. doi: 10.1038/cr.2012.25. Epub 2012 Feb 7. No abstract available.

20.

Redesign of the PAK1 autoinhibitory domain for enhanced stability and affinity in biosensor applications.

Jha RK, Wu YI, Zawistowski JS, MacNevin C, Hahn KM, Kuhlman B.

J Mol Biol. 2011 Oct 21;413(2):513-22. doi: 10.1016/j.jmb.2011.08.022. Epub 2011 Aug 24.

21.

Patterning pallet arrays for cell selection based on high-resolution measurements of fluorescent biosensors.

Shadpour H, Zawistowski JS, Herman A, Hahn K, Allbritton NL.

Anal Chim Acta. 2011 Jun 24;696(1-2):101-7. doi: 10.1016/j.aca.2011.04.012. Epub 2011 Apr 16.

22.

Homogeneous time-resolved fluorescence resonance energy transfer assay for measurement of Phox/Bem1p (PB1) domain heterodimerization.

Nakamura K, Zawistowski JS, Hughes MA, Sexton JZ, Yeh LA, Johnson GL, Scott JE.

J Biomol Screen. 2008 Jun;13(5):396-405. doi: 10.1177/1087057108318281. Epub 2008 May 14.

PMID:
18480472
23.

Neuronal expression of the Ccm2 gene in a new mouse model of cerebral cavernous malformations.

Plummer NW, Squire TL, Srinivasan S, Huang E, Zawistowski JS, Matsunami H, Hale LP, Marchuk DA.

Mamm Genome. 2006 Feb;17(2):119-28. Epub 2006 Feb 7.

PMID:
16465592
24.

Genetics of cerebral cavernous malformations.

Plummer NW, Zawistowski JS, Marchuk DA.

Curr Neurol Neurosci Rep. 2005 Sep;5(5):391-6. Review.

PMID:
16131422
25.

CCM1 and CCM2 protein interactions in cell signaling: implications for cerebral cavernous malformations pathogenesis.

Zawistowski JS, Stalheim L, Uhlik MT, Abell AN, Ancrile BB, Johnson GL, Marchuk DA.

Hum Mol Genet. 2005 Sep 1;14(17):2521-31. Epub 2005 Jul 21.

PMID:
16037064
26.

Loss of p53 sensitizes mice with a mutation in Ccm1 (KRIT1) to development of cerebral vascular malformations.

Plummer NW, Gallione CJ, Srinivasan S, Zawistowski JS, Louis DN, Marchuk DA.

Am J Pathol. 2004 Nov;165(5):1509-18.

27.

Mutations in a gene encoding a novel protein containing a phosphotyrosine-binding domain cause type 2 cerebral cavernous malformations.

Liquori CL, Berg MJ, Siegel AM, Huang E, Zawistowski JS, Stoffer T, Verlaan D, Balogun F, Hughes L, Leedom TP, Plummer NW, Cannella M, Maglione V, Squitieri F, Johnson EW, Rouleau GA, Ptacek L, Marchuk DA.

Am J Hum Genet. 2003 Dec;73(6):1459-64. Epub 2003 Nov 17.

28.

Vascular morphogenesis: tales of two syndromes.

Marchuk DA, Srinivasan S, Squire TL, Zawistowski JS.

Hum Mol Genet. 2003 Apr 1;12 Spec No 1:R97-112. Review.

PMID:
12668602
29.

KRIT1 association with the integrin-binding protein ICAP-1: a new direction in the elucidation of cerebral cavernous malformations (CCM1) pathogenesis.

Zawistowski JS, Serebriiskii IG, Lee MF, Golemis EA, Marchuk DA.

Hum Mol Genet. 2002 Feb 15;11(4):389-96.

PMID:
11854171

Supplemental Content

Loading ...
Support Center